Within the last quarter, Intra-Cellular Therapies ITCI has observed the following analyst ratings:

These 5 analysts have an average price target of $52.4 versus the current price of Intra-Cellular Therapies at $48.19, implying upside.

Below is a summary of how these 5 analysts rated Intra-Cellular Therapies over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This average price target has increased by 9.17% over the past month.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.